Related Experiment Video
Updated: Jul 20, 2026

Preparation of Human Myocardial Tissue for Long-Term Cultivation
Published on: June 2, 2022
Myocardial contractility after in vitro treatment with class III antiarrhythmic drug Nibentan
I A Latfullin1, R F Gaifullina, R K Dzhordzhikiya
1Kazan State Medical University.
Abstract:
Myocardial contractility was studied in vitro in response to treatment with class III antiarrhythmic drug Nibentan. The contractile response to Nibentan in increasing concentrations of 1.66, 2.5, and 3.5 mM was estimated on strips of animal myocardium and human right atrial auricle.
More Related Videos
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Heart Failure Drugs: Inotropic Agents
Myocarditis III: Medical Management
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...